UPMC Shadyside Family Health Center
Pittsburgh, Pennsylvania, 15232, United States
NCT Number: NCT03226509
Several factors are barriers to effective Hepatitis C care: 1) The majority of Hepatitis C Virus (HCV)-positive patients (45-85 percent) are unaware that they are infected; 2) Only a small minority of those in need of treatment receive it; 3) Members of minorities and older patients are even less likely to receive needed care; and 4) Until recently, even those who were treated had a low chance of clearing the virus or achieving cure; 5) It is possible that older attitudes and expectation of futility might continue to persist among patients and provider in primary care settings.
Community Health Centers are often the most culturally appropriate and accessible choices, particularly for underserved populations, with the benefit of ongoing trust and relationships with patients. Therefore, these can be ideal places to deliver complex HCV care if they possess the needed expertise. However, most community-based primary care and community health centers lack access to Hepatitis C evaluation and treatment services, leading to a major public health problem.
Thus, investigators propose to implement and evaluate a pragmatic trial to implement and evaluate a multi-disciplinary model for HCV treatment at Currently, the treatment initiation rates at each of these sites is estimated as less than 10%. The investigators hypothesize that our project will increase the rate of participation in all the steps of the HCV care cascade and ultimately lead to more than doubled rates of treatment uptake
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Pittsburgh, Pennsylvania, 15232, United States
Primary Objective:
Determine uptake, effectiveness and safety of IFN-free, DAAs among "real world" patients, including those with multiple comorbidities, in the primary care setting.
Secondary Objective(s):
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: three years
measure percentage of patients moving through the cascade of care to cure of condition (SVR 12)
Time frame: three years
Percentage of at risk patients in the practice who have a completed HCV antibody test
Time frame: three years
Percentage of patients with a positive HCV antibody test who have a HCV polymerase chain reaction (PCR) viral load completed
Time frame: three years
Percentage of consented patients with a positive HCV viral load who have a clinical evaluation and assessment of psychosocial readiness for treatment documented in the medical record
Time frame: three years
Percentage of patients recommended for treatment who begin medical treatment
Time frame: three years
Percentage of patients that began treatment who complete the recommended course of therapy
Time frame: three years
Percent of consented patients with a positive HCV viral load who are lost to follow up
Time frame: three years
Endpoints related to HCV capacity building among family medicine physicians: Evaluate comfort and skill among family physicians to evaluate and treat HCV infection as measured on a qualitative survey of physicians
University of Pittsburgh
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04943588
Blood-Borne Infections, Chronic Disease
Karachi, Pakistan
View Trial DetailsNCT05397067
Blood-Borne Infections, Chemically-Induced Disorders
Roanoke, Virginia, United States
View Trial DetailsNCT00148837
Blood-Borne Infections, Chronic Disease
Pessac, France
View Trial DetailsNCT04014179
Blood-Borne Infections, Chronic Disease
Bankstown, New South Wales, Australia
View Trial Details